BLAINTRAVENOUS, SUBCUTANEOUSINJECTABLE
Approved
Oct 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications (13)
more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)giant cell arteritis (GCA) in adult patientsactive polyarticular juvenile idiopathic arthritis in patients 2 years of ageolderactive systemic juvenile idiopathic arthritis in patients 2 years of agechimeric antigen receptor (CAR) T cell-induced severelife-threatening cytokine release syndrome in adultscoronavirus disease 2019 (COVID-19) in hospitalized adultrequire supplemental oxygennon-invasiveinvasive mechanical ventilationextracorporeal membrane oxygenation (ECMO)Rheumatoid Arthritis
Clinical Trials (5)
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Started Dec 2025
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Started Jul 2024
168 enrolled
Metastatic Breast CancerTriple Negative Breast CancerEstrogen-receptor-low Breast Cancer
Real World Use of Tocilizumab Biosimilar studY
Started Mar 2024
600 enrolled
Rheumatoid Arthritis
A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants
Started Jan 2024
300 enrolled
Healthy Volunteer
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Started Oct 2023
90 enrolled
Juvenile Idiopathic Arthritis